Michael McCaughan
4.4K posts
@RPMReportMike
Founding Member, Prevision Policy LLC Business Implications of FDA and CMS Policy; Policy Implications of Biopharma Business
$BMY to provide Eliquis to Medicaid for free
Questions on GLP-1 coverage in Medicare and Medicaid: (1) will there be coverage conditions (e.g., comorbidities)? (2) Will Part D plans have to cover? (3) Will plans be able to negotiate further price concessions? (4) When would coverage begin? (5) Will states have to cover?
@RPMReportMike But ... I'm understanding this as release of CRLs before an approval, so not part of an SBA. For example, if I wanted to know what really happened with the @kenvue @Haleon_health @nicorette Quickmist mouth spray (+ve AdComm vote in 2019), could an FDA document tell me? 🤷♂️
I bet @RPMReportMike has thoughts! This is a BFD, though we shall see what we see.
News: The FDA plans to publish rejection letters describing why medicines aren't approved that companies have mostly kept hidden until now via @damiangarde + @SamHornblower bloomberg.com/news/articles/…
